June 17, 2020 - The court granted in part and denying in part the defendants' motion to dismiss.

January 31, 2020 - A motion to dismiss the second amended complaint was filed.

December 9, 2019 - A second amended complaint was filed.

September 13, 2019 - An amended complaint was filed.

April 15, 2019 - An investor in shares of Teligent Inc (NASDAQ: TLGT) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Teligent Inc in connection with certain allegedly false and misleading statements made between May 2, 2017 and November 7, 2017.

Buena, NJ based Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. Teligent Inc reported that its annual Total Revenue rose from $44.25 million in 2015 to $63.01 million in 2016. On November 6, 2017, after the market closed, Teligent, Inc t filed a Form with the SEC disclosing disappointing third quarter 2017 earnings. Teligent, Inc reported that its Total revenue fell to $13.7 million from the previous quarter’s $18.4 million, a 25.5% drop, and from third quarter 2016’s $16.2 million, a 15.4% drop. Teligent’s earnings announcement quoted President and Chief Executive Officer Jason Grenfell-Gardner attributing the drop in revenue to FDA approval delays and competition. Shares of Teligent Inc (NASDAQ: TLGT) declined from $9.43 per share in June 2017 to as low as $2.82 per share in November 7, 2017.

According to the complaint the plaintiff alleges on behalf of purchasers of Teligent Inc (NASDAQ: TLGT) common shares between May 2, 2017 and November 7, 2017, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between May 2, 2017 and November 7, 2017, the Defendants made false and/or misleading statements regarding, and/or failed to disclose, product non-conformities in research and development and non-compliance with applicable regulations.